Aytu BioScience

Yahoo Finance • last month

Nutex Health Soars 21% After Hours On Revenue Surge; Biotech Peers Join Tuesday Gainers

(RTTNews) - Several small-cap biotech and pharma names posted notable gains in Tuesday's after-hours trading session, with Nutex Health standing out as the most significant mover following its quarterly results. Nutex Health Inc. (NUTX) s... Full story

Yahoo Finance • last month

Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Call Highlights: Strong ADHD Portfolio Performance ...

This article first appeared on GuruFocus. Release Date: November 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aytu BioPharma Inc (NASDAQ:AYTU) reported ne... Full story

Yahoo Finance • last month

Applied Therapeutics, Omeros, And Others Post Sharp Moves After Market Close

(RTTNews) - Several companies posted notable moves in after-hours trading on Thursday, driven by earnings announcements and regulatory updates. Shares of Milestone Scientific Inc. (MLSS) rose sharply in extended trading, climbing to $0.52... Full story

Yahoo Finance • last month

Aytu BioPharma outlines $10M EXXUA launch investment and targets breakeven at $17.3M quarterly revenue as ADHD franchise holds strong

Earnings Call Insights: Aytu BioPharma (AYTU) Q1 2026 MANAGEMENT VIEW * CEO Joshua Disbrow highlighted a "very positive and highly productive first quarter," with net revenue for the quarter at $13.9 million. Disbrow emphasized the str... Full story

Yahoo Finance • last month

Here are the major earnings after the close Thursday

Major earnings expected after the bell on Thursday include: * Applied Materials (AMAT [https://seekingalpha.com/symbol/AMAT]) * Virgin Galactic Holdings (SPCE [https://seekingalpha.com/symbol/SPCE]) * Nu Holdings Ltd. (NU [https://s... Full story

Yahoo Finance • last month

Aytu BioPharma Q1 2026 Earnings Preview

* Aytu BioPharma (AYTU [https://seekingalpha.com/symbol/AYTU]) is scheduled to announce Q1 earnings results on Thursday, November 13th, after market close. * The consensus EPS Estimate is -$0.20 [https://seekingalpha.com/symbol/AYTU/ea... Full story

Yahoo Finance • 3 months ago

Aytu outlines EXXUA launch targeting $22B MDD market while streamlining ADHD portfolio

Earnings Call Insights: Aytu BioPharma (AYTU) Q4 2025 MANAGEMENT VIEW * CEO Joshua Disbrow highlighted "the strong financial performance during the recent fiscal year and perhaps more importantly, the upcoming launch of EXXUA, which we... Full story

Yahoo Finance • 3 months ago

Aytu BioPharma GAAP EPS of -$2.93 misses by $2.88, revenue of $15.1M misses by $2.82M

* Aytu BioPharma press release [https://seekingalpha.com/pr/20242010-aytu-biopharma-reports-fiscal-2025-full-year-and-fourth-quarter-operational-and-financial] (NASDAQ:AYTU [https://seekingalpha.com/symbol/AYTU]): Q4 GAAP EPS of -$2.93 m... Full story

Yahoo Finance • 3 months ago

Aytu BioPharma FQ4 2025 Earnings Preview

* Aytu BioPharma (NASDAQ:AYTU [https://seekingalpha.com/symbol/AYTU]) is scheduled to announce FQ4 earnings results on Tuesday, September 23rd, after market close. * The consensus EPS Estimate is -$0.06 [https://seekingalpha.com/symbol... Full story

Yahoo Finance • 5 months ago

Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition

Aytu BioPharma, Inc. (NASDAQ:AYTU) is one of the best high-return penny stocks to buy now. On July 1, Lake Street Capital Markets initiated coverage on Aytu Biosciences (NASDAQ:AYTU) with a Buy rating and an $8.00 price target, citing stro... Full story

Yahoo Finance • 7 months ago

Aytu BioPharma to commercialise Exxua for MDD in the US

Aytu BioPharma has signed an exclusive agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua (gepirone) extended-release tablets, a new antidepressant, to the US market for major depressive disorder (MDD). Exxua, developed by... Full story

Yahoo Finance • 2 years ago

Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Company Expects a Six-Month Review of the Prior Approval Supplement Submission by the U.S. Food & Drug Administration Which, if Approved, Enables the Transfer of Cotempla Production to Contract Manufacturer Upon Completion of Manufacturin... Full story

Yahoo Finance • 3 years ago

Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market

Abhinav Jain of Nantahala Capital Management, LLC Joins the Company's Board of Directors Upon Closing Potential for Additional $7 Million in Event of Exercise of Common Warrants in Full Extends Interest Only Period on Avenue Capital Term... Full story